Braveheart Bio has had a rough stretch on the market so far this year, and with the share price under pressure, the open question is how well that market value lines up with what the company currently shows on its balanc
Why Is BRVE (BRVE) Stock Up Today?
Updated Nov 22, 2026 7:42 AM ET ยท Prev Close $19.27
Session Regime & Catalyst Assessment
68% Signal ConvictionBRVE Advancing 5.81% on 1.67x Relative Volume
Brve (Brve) is advancing 5.81% (+$1.12) to $20.39 on 1.67x average session volume. Relative to benchmarks, BRVE is outperforming the S&P 500 by +9.45%. 14-day RSI stands at 50.8, keeping momentum in a bullish regime.
Braveheart Bio has had a rough stretch on the market so far this year, and with the share price under pressure, the open question is how well that market value lines up with what the company currently shows on its balanc
Price ($20.39) trades relative to 20-day SMA ($20.16) and 50-day SMA ($21.23).
Market & Sector Relative Strength
BRVE outperforming the S&P 500 by +9.45%Options Flow & Execution Desk
Recent BRVE Catalyst Headlines
Verified WireBraveheart Bio BRVE has drawn fresh attention after its clinical-stage focus on hypertrophic cardiomyopathy put its experimental cardiac myosin inhibitor programs in the spotlight for investors tracking specialized cardi
52-week data presented at AHA Scientific Sessions 2026 further strengthen Bhb-1893 s potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen Lionheart-Hcm oHCM Pha
San Francisco, Nov. 09, 2026 Globe Newswire -- Braveheart Bio, Inc. Nasdaq BRVE , a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy HCM and other serious c
1โ3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $20.16 (20-day SMA support) for directional breakout confirmation.
Technical Regime (BRVE)
MIXED MA TRENDAbout BRVE
Get Instant BRVE Catalyst Alerts
Receive an email alert when BRVE triggers an unusual volume breakout, options sweep, or rating shift.
BRVE Session & Catalyst FAQ
Why is BRVE stock up today?
Brve (Brve) is advancing 5.81% (+$1.12) to $20.39 on 1.67x average session volume. Relative to benchmarks, BRVE is outperforming the S&P 500 by +9.45%. 14-day RSI stands at 50.8, keeping momentum in a bullish regime.
Is BRVE stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 1.67x relative volume (high participation). Our multi-factor model currently rates BRVE as AVOID NEW MONEY. Review full valuation, quality, and timing signals on the BRVE Buy or Sell Decision Brief โ
What is BRVE's intrinsic value and expected trading range?
At $20.39, BRVE's modeled 1-to-3 session range is $19.27 โ $21.51, with a key inflection level at $20.16 (20-day SMA support). Compare current price against multi-year cash flow projections in the BRVE Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for BRVE?
RSI at 50.8 reflects constructive bullish momentum. BRVE trades at $20.39 relative to its 20-day SMA ($20.16) and 50-day SMA ($21.23), reflecting a mixed moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.